TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the JMP Securities Life Sciences Conference on June 16^th, 2022.

TELA Bio’s management is scheduled to present at the JMP Securities Life Sciences Conference on Thursday, June 16^th, 2022, at 11:00am ET. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Investor Contact
Greg Chodaczek
332-895-3230
[email protected]

You May Also Be Interested In

• A Race Against Blindness Launches Luxury Ford F-250 Fundraising Drive to Cure Childhood Blindness 
• Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• TEGNA Stations Receive Four National Edward R. Murrow Awards